コンテンツへスキップ
Merck
  • Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma.

Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma.

Pharmacogenomics (2005-07-15)
Shane C McAllister, Klaus Früh, Ashlee V Moses
要旨

Kaposi's sarcoma (KS) is a multifocal angioproliferative disorder affecting the skin, mucosa and viscera of individuals infected with human herpesvirus-8 (HHV-8; also Kaposi's sarcoma-associated herpesvirus [KSHV]). KS is the most common neoplasm in AIDS patients; the clinical outcome of AIDS-KS is significantly improved by highly active antiretroviral therapy (HAART). However, in Africa, where the severest manifestations of KS occur, there is limited access to these and other effective but expensive drugs. Here we present a review of current efforts to identify novel therapeutic targets for the treatment of KS using functional genomics, with recommendations regarding the development of economically feasible treatments for use in Africa.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
メゾポルフィリンIX 二塩酸塩, synthetic, 95%